CJC-1295 with DAC (Drug Affinity Complex) is a modified version of CJC-1295, a synthetic peptide that mimics the action of growth hormone-releasing hormone (GHRH). The addition of the DAC component enables the peptide to bind covalently to albumin in the bloodstream, dramatically extending its half-life—often up to 7–10 days—compared to the few minutes seen with native GHRH.

This extended duration allows for sustained pulsatile release of endogenous growth hormone (GH) and a corresponding increase in insulin-like growth factor 1 (IGF-1) levels. Research has focused on its effects in promoting anabolic processes, lipid metabolism, muscle regeneration, and connective tissue repair. Because it stimulates the natural GH feedback loop, CJC-1295 with DAC is of interest in studies seeking to enhance physiological hormone profiles without full suppression of the pituitary axis.

Its long-acting nature and ability to support endogenous GH release make it a promising agent in research involving regenerative medicine, anti-aging therapies, and metabolic regulation.